RSV maternal vaccine study in Scottish newborns
Treatments studied
Part of Infections clinical trials.
This study looks at how well a maternal RSV vaccine (ABRYSVO) works by using health records of babies born in Scotland. It helps determine if vaccinating pregnant people can protect newborns from severe RSV disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be born alive in Scotland between September 1, 2024 and February 28, 2026.
- Your baby must be at least 28 weeks into pregnancy when born (full weeks of pregnancy).
- You did not get any RSV vaccine during pregnancy other than ABRYSVO (Pfizer's RSV vaccine).
- Your baby did not receive a special antibody shot (like nirsevimab or palivizumab) to prevent RSV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests an RSV vaccine (BLB-201) in infants and young children. It aims to see how the vaccine works and how safe it is, including in children who already have RSV antibodies or not.
This study tests an experimental RSV vaccine (IN006) in healthy adults to check its safety and how well it triggers an immune response. It may help protect against respiratory syncytial virus (RSV), which can cause serious lung infections.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This trial tests two ways to protect babies from RSV: a vaccine given to pregnant women, and an antibody shot given to newborns. Both are already approved—this study checks if using them together works better than either alone.
This trial tests a new vaccine (MKK900) to see if it is safe and works well in healthy adult women. It is designed to protect against RSV, a common virus that can be serious in newborns and older adults. The vaccine is being developed for use during pregnancy to pass protection to babies.
This study tests an approved RSV vaccine given to pregnant women. The goal is to see if it safely protects their babies from severe RSV lung infections during the first months of life.
Hear when a new Respiratory Syncytial Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.